[go: up one dir, main page]

MX2020008039A - Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer. - Google Patents

Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.

Info

Publication number
MX2020008039A
MX2020008039A MX2020008039A MX2020008039A MX2020008039A MX 2020008039 A MX2020008039 A MX 2020008039A MX 2020008039 A MX2020008039 A MX 2020008039A MX 2020008039 A MX2020008039 A MX 2020008039A MX 2020008039 A MX2020008039 A MX 2020008039A
Authority
MX
Mexico
Prior art keywords
cells
natural killer
composition
treating cancer
killer cells
Prior art date
Application number
MX2020008039A
Other languages
English (en)
Other versions
MX386373B (es
Inventor
Sang Woo Park
Yong Man Kim
Jae Seob Jung
Yong-Hee Rhee
Original Assignee
Nkmax Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020190001981A external-priority patent/KR102732845B1/ko
Priority claimed from KR1020190001983A external-priority patent/KR102765799B1/ko
Application filed by Nkmax Co Ltd filed Critical Nkmax Co Ltd
Priority claimed from PCT/US2019/016076 external-priority patent/WO2019152663A1/en
Publication of MX2020008039A publication Critical patent/MX2020008039A/es
Publication of MX386373B publication Critical patent/MX386373B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0646—Natural killers cells [NK], NKT cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2013—IL-2
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/15—Natural-killer [NK] cells; Natural-killer T [NKT] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/50—Colon
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/105—Insulin-like growth factors [IGF]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/125—Stem cell factor [SCF], c-kit ligand [KL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2302—Interleukin-2 (IL-2)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2304—Interleukin-4 (IL-4)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2307—Interleukin-7 (IL-7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2315—Interleukin-15 (IL-15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2318—Interleukin-18 (IL-18)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C12N2501/2321—Interleukin-21 (IL-21)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/26—Flt-3 ligand (CD135L, flk-2 ligand)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2502/00—Coculture with; Conditioned medium produced by
    • C12N2502/11—Coculture with; Conditioned medium produced by blood or immune system cells
    • C12N2502/1114—T cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2506/00—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells
    • C12N2506/11—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells
    • C12N2506/115—Differentiation of animal cells from one lineage to another; Differentiation of pluripotent cells from blood or immune system cells from monocytes, from macrophages

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Zoology (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención se refiere a un método para producir células asesinas naturales (NK). El método comprende aislar células mononucleares de sangre periférica (PBMCs) de una muestra de sangre; aislar al menos una de las células CD56+ y/o células CD3-/CD56+ de las PBMCs; y cocultivar la al menos una de las células CD56+ y/o células CD3-/CD56+ con una combinación de células alimentadoras en presencia de una citocina. También se describe una composición para tratar el cáncer. La composición comprende las células asesinas naturales CD56+ producidas por el método de la presente invención y una citocina.
MX2020008039A 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer. MX386373B (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR20180012938 2018-02-01
KR20180012942 2018-02-01
KR1020190001981A KR102732845B1 (ko) 2018-02-01 2019-01-07 자연살해세포의 생산방법
KR1020190001983A KR102765799B1 (ko) 2018-02-01 2019-01-07 Cd56+ 자연살해세포를 포함하는 항암용 조성물
PCT/US2019/016076 WO2019152663A1 (en) 2018-02-01 2019-01-31 Method of producing natural killer cells and composition for treating cancer

Publications (2)

Publication Number Publication Date
MX2020008039A true MX2020008039A (es) 2021-09-20
MX386373B MX386373B (es) 2025-03-18

Family

ID=68465207

Family Applications (2)

Application Number Title Priority Date Filing Date
MX2020008039A MX386373B (es) 2018-02-01 2019-01-31 Método para producir células asesinas naturales (nk) y composición para el tratamiento de cáncer.
MX2021004682A MX2021004682A (es) 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Family Applications After (1)

Application Number Title Priority Date Filing Date
MX2021004682A MX2021004682A (es) 2018-02-01 2020-07-30 Metodo para producir celulas asesinas naturales (nk) y composicion para el tratamiento de cancer.

Country Status (15)

Country Link
US (4) US10590385B2 (es)
EP (1) EP3746095A4 (es)
JP (3) JP7268039B2 (es)
CN (2) CN111757745B (es)
AU (2) AU2019215034C1 (es)
BR (1) BR112020015512A2 (es)
CA (1) CA3089853A1 (es)
CL (1) CL2020002011A1 (es)
IL (1) IL276365B2 (es)
MX (2) MX386373B (es)
MY (2) MY197176A (es)
NZ (1) NZ766453A (es)
PH (1) PH12020551151A1 (es)
SA (1) SA520412566B1 (es)
SG (1) SG11202007221QA (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9938498B2 (en) * 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
US11504396B2 (en) 2016-12-21 2022-11-22 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
CN114929249A (zh) * 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
CN112626029B (zh) * 2020-12-22 2022-12-20 深圳市赛欧细胞技术有限公司 一种转基因修饰的Daudi细胞及其制备方法、应用
WO2022250312A1 (ko) * 2021-05-27 2022-12-01 (주)에스엠티바이오 신경내분비종양의 치료용 자연살해세포
WO2024036226A1 (en) * 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells
CN117122612B (zh) * 2023-07-07 2024-08-27 河络新图生物科技(上海)有限公司 外周血单个核细胞在制备治疗/预防阿尔茨海默病的药物中的用途
CN116904397B (zh) * 2023-09-04 2023-12-26 山东德升细胞治疗工程技术有限公司 Nk细胞的细胞外囊泡的制备及应用

Family Cites Families (116)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1320906C (en) 1986-06-04 1993-08-03 Daniel R. Twardzik Interleukin-2 induced antineoplastic peptide
EP0460101A4 (en) 1989-02-24 1992-04-15 Immunotherapeutics, Inc. Immobilized cytokines
GR1001034B (el) 1989-07-21 1993-03-31 Ortho Pharma Corp Μεθοδος διεγερσης του πολλαπλασιασμου λεμφοκυτταρων περιφερειακου αιματος.
US5415874A (en) 1989-10-31 1995-05-16 The Board Of Trustees Of The Leland Stanford Junior University Natural killer cell lines and clones with antigen specificity
WO1998005795A1 (en) 1996-08-02 1998-02-12 The Center For Blood Research, Inc. Enrichment of dendritic cells from blood
DE19813759C1 (de) 1998-03-27 1999-07-15 Gsf Forschungszentrum Umwelt Verfahren zur Induktion einer durch NK-Zellen vermittelten Immunantwort
US6307024B1 (en) 1999-03-09 2001-10-23 Zymogenetics, Inc. Cytokine zalpha11 Ligand
EP1409650B1 (en) 2001-05-30 2006-04-12 Fondazione Telethon Ex-vivo isolated cd25+cd4+ t cells with immunosuppressive activity and uses thereof
US20030068306A1 (en) 2001-09-14 2003-04-10 Dilber Mehmet Sirac Medium
US7544355B2 (en) 2002-03-13 2009-06-09 Universita Degli Studi Di Perugia Methods and compositions for allogeneic transplantation
EP1531850B1 (en) 2002-06-07 2012-02-22 ZymoGenetics, Inc. Use of IL-21 and monoclonal antibody for treating solid cancers
EP2865386B1 (en) 2002-07-18 2017-07-05 University of Washington Pharmaceutical compositions comprising immunologically active herpes simplex virus (HSV) protein fragments
US20050191743A1 (en) 2002-10-03 2005-09-01 Wu J.H. D. Three-dimensional peripheral lymphoid organ cell cultures
JP4033390B2 (ja) 2002-10-30 2008-01-16 独立行政法人科学技術振興機構 不死化ナチュラルキラー細胞株
WO2006004592A2 (en) 2004-05-28 2006-01-12 Mayo Foundation For Medical Education And Research Methods for autologous stem cell transplantation
US20090104170A1 (en) 2004-11-02 2009-04-23 Richard William Wyatt Childs Compositions and methods for treating hyperproliferative disorders
EP1817022B1 (en) 2004-11-24 2018-04-25 Hill's Pet Nutrition, Inc. Methods for increasing the immune response in an animal
JP5663135B2 (ja) 2005-03-17 2015-02-04 ユーシーエル ビジネス ピーエルシー 腫瘍細胞調製物によってｉｎｖｉｔｒｏでナチュラルキラー細胞を活性化させるための方法
SI1739166T1 (sl) 2005-07-01 2011-11-30 Txcell S A PRIDOBIVANJE CELIC Tr1 SPECIFIČNIH ZA ALIMENTARNI ANTIGEN ALI AVTOGEN IZ LEVKOCITNE ALI PBMC POPULACIJE
US9121008B2 (en) 2005-08-31 2015-09-01 University Of Utah Research Foundation Development of natural killer cells and functional natural killer cell lines
PT1941027E (pt) 2005-09-28 2014-10-09 Ipd Therapeutics B V Métodos e meios para proliferação de células estaminais e subsequente geração e expansão de células progenitoras, bem como produção de células efectoras como produtos terapêuticos clínicos
AU2007223093A1 (en) 2006-03-06 2007-09-13 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Autologous natural killer cells and lymphodepleting chemotherapy for the treatment of cancer
EP2139498B1 (en) 2007-03-22 2015-03-18 Dendreon Corporation Methods for detecting a natural killer (nk) cell-mediated immune response and an increase in nk cell activity
PL2142642T3 (pl) 2007-03-27 2017-10-31 Ipd Therapeutics B V Sposoby i środki do proliferacji komórek macierzystych oraz następczego wytwarzania i ekspansji komórek progenitorowych, jak również wytwarzania komórek efektorowych jako leków klinicznych
KR100902340B1 (ko) 2007-08-02 2009-06-12 한국생명공학연구원 Ｙｃ－１ 또는 ｉｌ－２１을 유효성분으로 포함하는자연살해세포 분화제 및 분화 방법
JP5456689B2 (ja) 2007-12-07 2014-04-02 ミルテンイ バイオテック ゲーエムベーハー 試料を少なくとも２つの成分に分離する遠心分離機
KR101133185B1 (ko) 2008-07-29 2012-04-06 서울대학교병원 자연살해세포의 증식방법
KR101077912B1 (ko) * 2008-10-24 2011-10-31 주식회사 메디셀 제대혈로부터 효율적인 자연살해세포의 증식 및 분화 방법
CA2753679C (en) 2009-02-27 2021-03-02 Cellular Dynamics International, Inc. Differentiation of pluripotent cells
CN102428173B (zh) 2009-03-26 2014-07-30 细胞维护北欧制药公司 Nk细胞的扩增
TW201127959A (en) 2010-02-12 2011-08-16 Ivy Life Sciences Co Ltd Method of producing immune killer cell
AU2010347018A1 (en) 2010-02-24 2012-09-20 Ingo Schmidt-Wolf Method for the generation of a CIK cell and NK cell population
AU2011279201B2 (en) 2010-07-13 2016-01-21 Celularity Inc. Methods of generating natural killer cells
KR101145391B1 (ko) 2010-08-16 2012-05-15 고려대학교 산학협력단 말초혈액으로부터 자연 살해세포의 증식 방법
TWI439275B (zh) 2010-12-31 2014-06-01 Glory Biomedical Co Ltd 一種人類自然殺手細胞之體外增殖方法
KR20120093002A (ko) 2011-02-14 2012-08-22 (주)에이티젠 Ｎｋ 세포의 활성 측정을 이용한 암 진단 방법 및 진단 키트
DK2686421T3 (da) 2011-03-18 2021-03-08 Glycostem Therapeutics B V Generering af nk-celler og nk-celleforløbere
JP5572863B2 (ja) * 2011-06-24 2014-08-20 国立大学法人九州大学 Ｎｋ細胞の増幅方法
CN104204194B (zh) 2011-12-22 2018-08-03 财团法人牧岩生命工学研究所 生产自然杀伤细胞的方法、由该方法生产的自然杀伤细胞以及包含该自然杀伤细胞的用于治疗癌症和感染性疾病的组合物
PL2812011T3 (pl) 2012-02-08 2020-06-29 Glycostem Therapeutics B.V. Różnicowanie komórek NK z komórek hematopoetycznych CD34<sup>+</sup> ex vivo
EP3567102A1 (en) 2012-04-24 2019-11-13 Dan S. Kaufman Method for developing natural killer cells from stem cells
US9938498B2 (en) * 2012-05-07 2018-04-10 Nkmax Co., Ltd. Method for the induction and expansion of natural killer cells derived from peripheral blood mononuclear cells
EP3578201B1 (en) 2012-06-28 2023-04-19 University Of Central Florida Research Foundation Incorporated Methods and compositions for natural killer cells
US9175266B2 (en) * 2012-07-23 2015-11-03 Gamida Cell Ltd. Enhancement of natural killer (NK) cell proliferation and activity
JP5856025B2 (ja) 2012-08-02 2016-02-09 阿部　博幸 単球またはｎｋ細胞を入手する方法
CN102988415B (zh) 2012-08-15 2014-11-19 中航（宁夏）生物有限责任公司 人异基因有核细胞工业化制备自然杀伤性细胞(nk)及注射液
PL2923208T3 (pl) 2012-11-21 2019-09-30 Institut National De La Santé Et De La Recherche Médicale (Inserm) Sposoby określania ryzyka ostrej choroby przeszczep przeciwko gospodarzowi
HK1210806A1 (en) 2013-01-15 2016-05-06 阿部博幸 Method for manufacturing immunocyte-containing composition, and cancer-treating composition
US9763983B2 (en) * 2013-02-05 2017-09-19 Anthrogenesis Corporation Natural killer cells from placenta
US9546203B2 (en) 2013-03-14 2017-01-17 Amgen Inc. Aglycosylated Fc-containing polypeptides with cysteine substitutions
DK2986312T3 (da) 2013-04-19 2022-02-14 Cytune Pharma Cytokinafledt behandling med reduceret vaskulært lækagesyndrom
JP6417413B2 (ja) 2013-10-17 2018-11-07 ナショナル ユニヴァーシティー オブ シンガポール 多様な腫瘍に対する抗体依存性細胞毒性を誘発するキメラ受容体
CN106103701B (zh) 2014-01-03 2020-04-24 中央研究院 改造的自然杀手细胞及其组成与用途
WO2015125113A1 (en) 2014-02-21 2015-08-27 Dr. Reddy's Laboratories Limited Method of culturing high cell density pbmc's
DK3114215T3 (da) * 2014-03-07 2021-06-21 Emercell Sas Grupperede nk-celler fra navlestrengsblod og anvendelse deraf til behandling af cancer og kronisk infektionssygdom
WO2015154012A1 (en) 2014-04-03 2015-10-08 Memorial Sloan-Kettering Cancer Center Clonogenic natural killer (nk) cell populations and methods of producing and using such populations
KR20210014210A (ko) 2014-05-15 2021-02-08 내셔널 유니버시티 오브 싱가포르 변형된 천연 살해 세포 및 그의 용도
JP7413639B2 (ja) 2014-06-11 2024-01-16 ポリバイオセプト ゲーエムベーハー 能動的細胞免疫療法のためのサイトカイン組成物を用いたリンパ球の増殖
JP2016008198A (ja) 2014-06-24 2016-01-18 国立大学法人名古屋大学 間質性膀胱炎の治療
SG11201610699XA (en) 2014-07-07 2017-01-27 Targazyme Inc Manufacture and cryopreservation of fucosylated cells for therapeutic use
JP2016077185A (ja) 2014-10-14 2016-05-16 学校法人 聖マリアンナ医科大学 γδＴ細胞の製造方法および医薬
DK3221349T3 (da) 2014-11-19 2021-01-04 Axon Neuroscience Se Humaniserede tau-antistoffer i Alzheimers sygdom
EP3034092A1 (en) 2014-12-17 2016-06-22 Université de Lausanne Adoptive immunotherapy for treating cancer
AU2015374062B2 (en) 2014-12-31 2021-05-06 Celgene Corporation Methods of treating hematological disorders, solid tumors, or infectious diseases using natural killer cells
WO2016122014A1 (ko) 2015-01-27 2016-08-04 한국생명공학연구원 자연살해세포의 대량생산 방법 및 상기 방법으로 수득된 자연살해세포의 항암제로서의 용도
CN104705291A (zh) 2015-04-03 2015-06-17 广州赛莱拉干细胞科技股份有限公司 一种脐血单个核细胞冻存液、应用、制备方法
GB201509202D0 (en) 2015-05-28 2015-07-15 Ge Healthcare Bio Sciences Ab Semi-static cell culture
WO2016209021A1 (ko) 2015-06-24 2016-12-29 주식회사 차바이오텍 자연살해세포의 증식 방법 및 자연살해세포 증식용 조성물
KR101851270B1 (ko) 2015-07-10 2018-04-25 고려대학교 산학협력단 자연 살해세포의 대량증식 방법 및 배양용 조성물
EP3138905A1 (en) 2015-09-04 2017-03-08 Miltenyi Biotec GmbH Method for natural killer cell expansion
EP3389712B1 (en) 2015-12-17 2024-04-10 Novartis AG Antibody molecules to pd-1 and uses thereof
CN105524880A (zh) 2016-01-27 2016-04-27 上海润泉生物技术有限公司 一种免疫细胞库的构建方法
CN107267454B (zh) 2016-04-07 2025-05-23 内蒙古原生元生物科技有限公司 一种脐血nk细胞的体外扩增方法及其试剂盒与应用
KR101968184B1 (ko) * 2016-04-29 2019-04-15 고려대학교 산학협력단 저산소 조건을 이용한 면역세포의 증식 배양 방법
CA3023239A1 (en) * 2016-05-07 2017-11-16 Celularity Inc. Methods of treating acute myeloid leukemia and multiple myeloma using natural killer cells
JP7086928B2 (ja) 2016-07-25 2022-06-20 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ 改変されたナチュラルキラー細胞を生成する方法および使用方法
KR102650803B1 (ko) 2016-10-05 2024-03-25 유니버시티 오브 센트럴 플로리다 리서치 파운데이션, 인코포레이티드 Nk 세포 및 항-pdl1 암 요법과 관련된 방법 및 조성물
US10300089B2 (en) 2016-11-08 2019-05-28 University Of Central Florida Research Foundation, Inc. Methods for high scale therapeutic production of memory NK cells
US11504396B2 (en) 2016-12-21 2022-11-22 Nkmax Co., Ltd. Pharmaceutical composition and methods comprising immune cells and ponatinib
WO2018161026A1 (en) * 2017-03-03 2018-09-07 Obsidian Therapeutics, Inc. Il15 compositions and methods for immunotherapy
KR101948534B1 (ko) 2017-04-20 2019-02-15 주식회사 이뮤니스바이오 세포밀도 조절을 이용한 자연살해세포의 대량증식방법
CN110662834B (zh) 2017-05-26 2023-09-12 Gc细胞治疗 使用转化的t细胞培养自然杀伤细胞的方法
WO2019014684A1 (en) 2017-07-14 2019-01-17 Ohio State Innovation Foundation EXPANSION OF IMMUNE CELLS WITH INTERLEUKIN-INDUCIBLE T CELL KINASE-INHIBITING COMPOUNDS
KR20250130723A (ko) 2017-08-03 2025-09-02 신톡스, 인크. 증식성 질환 및 감염성 질환의 치료를 위한 사이토카인 접합체
WO2019046444A2 (en) 2017-08-29 2019-03-07 Flaask, Llc COMPOSITIONS AND METHODS FOR DIAGNOSING SENSITIVITY TO AUTISM SPECTRUM DISORDER (ASD), REDUCING THE PROBABILITY OF DEVELOPING ASD AND / OR TREATING ASD
CN107970258B (zh) 2017-11-20 2020-11-10 英普乐孚生物技术(上海)有限公司 一种嵌合抗原受体t细胞制剂
KR102765799B1 (ko) 2018-02-01 2025-02-13 주식회사 엔케이맥스 Cd56+ 자연살해세포를 포함하는 항암용 조성물
EP3746095A4 (en) 2018-02-01 2021-04-21 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
WO2019152663A1 (en) 2018-02-01 2019-08-08 Nkmax Co., Ltd. Method of producing natural killer cells and composition for treating cancer
KR102732845B1 (ko) 2018-02-01 2024-11-25 주식회사 엔케이맥스 자연살해세포의 생산방법
TWI899050B (zh) 2018-02-21 2025-10-01 美國德克薩斯大學系統評議委員會 通用抗原呈現細胞及其用途
WO2019168222A1 (ko) 2018-02-28 2019-09-06 주식회사 제넨셀 말초혈액단핵구 유래 항암 활성화 림프구 배양용 배지 조성물 및 이를 이용한 항암 활성화 림프구 배양방법
EP3765519B1 (en) 2018-03-13 2024-01-17 Fundación para la Investigación Biomédica del Hospital Universitario la Paz Anti-cxcr4 antibody combined with activated and expanded natural killer cells for cancer immunotherapy
EP3539552A1 (en) 2018-03-16 2019-09-18 Deutsches Rheuma-Forschungszentrum Berlin Activation and expansion of nkg2c+ nk cells
WO2019182392A1 (ko) 2018-03-23 2019-09-26 주식회사 녹십자랩셀 자연살해세포의 제조방법
MX2020011697A (es) 2018-05-03 2020-12-10 Univ Texas Células exterminadoras naturales diseñadas para expresar receptores de antígeno quimérico con bloqueo de punto de control inmunitario.
JP2021525066A (ja) 2018-05-30 2021-09-24 グリコステム セラピューティクス ベスローテン フェンノートシャップ Ｃａｒ ｎｋ細胞
WO2020006139A1 (en) 2018-06-27 2020-01-02 The George Washington University Targeting stat sumoylation to enhance immune responses
US11419898B2 (en) 2018-10-17 2022-08-23 Senti Biosciences, Inc. Combinatorial cancer immunotherapy
CN109294985B (zh) 2018-10-25 2022-02-18 江苏普瑞康生物医药科技有限公司 一种用于nk细胞体外扩增的培养基体系及nk细胞体外扩增的方法
EA202190871A1 (ru) 2018-11-08 2021-09-15 Гаммадельта Терапьютикс Лимитед Способы выделения и размножения клеток
WO2020101361A1 (ko) 2018-11-14 2020-05-22 주식회사 녹십자랩셀 형질전환된 t세포를 이용한 제대혈 유래 자연살해세포의 배양방법
CN111205361B (zh) 2018-11-22 2022-05-06 海珂分子（北京）科技有限责任公司 白介素21蛋白(il21)突变体及其应用
EP3656851A1 (en) 2018-11-23 2020-05-27 Technische Universität Dresden Artificial hla-positive feeder cell lines for nk cells and uses thereof
US20220047635A1 (en) 2018-11-26 2022-02-17 Nkarta, Inc. Methods for the simultaneous expansion of multiple immune cell types, related compositions and uses of same in cancer immunotherapy
MX2021006393A (es) 2018-11-29 2021-10-13 Univ Texas Metodos para expansion ex vivo de celulas exterminadoras naturales y uso de las mismas.
US20220089667A1 (en) 2019-01-07 2022-03-24 Inhibrx, Inc. Polypeptides Comprising Modified IL-2 Polypeptides and Uses Thereof
CN113710691B (zh) 2019-02-20 2025-03-04 罗格斯新泽西州立大学 自然杀伤和嵌合抗原受体修饰的细胞的扩增
CU24712B1 (es) 2019-03-15 2024-07-10 Centre Hospitalier Univ Vaudois Método para la expansión y diferenciación de linfocitos t y células nk en terapias de transferencia adoptiva
BR112021019411A2 (pt) 2019-03-29 2021-11-30 Univ Texas Métodos para a produção de células car-nk e uso das mesmas
CA3142952A1 (en) 2019-06-25 2020-12-30 City Of Hope Pdl1 positive nk cell cancer treatment
CN114929249A (zh) 2019-11-29 2022-08-19 Nkmax有限公司 产生自然杀伤细胞及其组合物的方法
US20250195574A1 (en) 2022-06-02 2025-06-19 Nkmax Co., Ltd. Method for reduction of immune checkpoint therapy related adverse events
KR20250044875A (ko) 2022-07-12 2025-04-01 주식회사 엔케이맥스 확장된 자연살해세포를 이용한 파킨슨병 치료방법
WO2024036005A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating alzheimer's disease with expanded natural killer cells
WO2024036226A1 (en) 2022-08-10 2024-02-15 Nkmax Co., Ltd. Method of treating autism with expanded natural killer cells

Also Published As

Publication number Publication date
CN111757745A (zh) 2020-10-09
US11066644B2 (en) 2021-07-20
JP7339309B2 (ja) 2023-09-05
RU2020128764A3 (es) 2022-03-01
IL276365B1 (en) 2023-06-01
IL276365A (en) 2020-09-30
IL276365B2 (en) 2023-10-01
US20250059510A1 (en) 2025-02-20
JP2022000060A (ja) 2022-01-04
JP7669434B2 (ja) 2025-04-28
US12098388B2 (en) 2024-09-24
US20200172869A1 (en) 2020-06-04
CA3089853A1 (en) 2019-08-08
MY197176A (en) 2023-05-30
AU2019215034B2 (en) 2021-08-19
JP2023153361A (ja) 2023-10-17
JP2021506333A (ja) 2021-02-22
RU2020128764A (ru) 2022-03-01
AU2021266198B2 (en) 2024-12-19
CN115710576A (zh) 2023-02-24
AU2019215034C1 (en) 2022-01-06
AU2021266198A1 (en) 2021-12-02
SG11202007221QA (en) 2020-08-28
MY199514A (en) 2023-11-02
US10590385B2 (en) 2020-03-17
JP7268039B2 (ja) 2023-05-02
US20190345449A1 (en) 2019-11-14
US20210032597A1 (en) 2021-02-04
SA520412566B1 (ar) 2025-05-11
NZ766453A (en) 2022-02-25
CN111757745B (zh) 2022-11-04
MX2021004682A (es) 2021-06-04
EP3746095A4 (en) 2021-04-21
EP3746095A1 (en) 2020-12-09
MX386373B (es) 2025-03-18
PH12020551151A1 (en) 2021-09-01
CL2020002011A1 (es) 2021-02-12
AU2019215034A1 (en) 2020-08-27
BR112020015512A2 (pt) 2021-01-26

Similar Documents

Publication Publication Date Title
PH12020551151A1 (en) Method of producing natural killer cells and composition for treating cancer
PH12020551923A1 (en) Methods and compositions for treating cancer
TN2019000289A1 (en) Treatment of asthma with anti-tslp antibody
MX2021013218A (es) Composiciones y metodos para el tratamiento del cancer usando una terapia con celulas t modificadas con tet2.
PH12020551932A1 (en) Methods of treating cancers and enhancing efficacy of t cell redirecting therapeutics
BR112018076263A2 (pt) composições e métodos para a depleção de células
EP3927370B8 (en) Methods for producing autologous t cells useful to treat cancers and compositions thereof
PH12021551036A1 (en) Anti-liv1 immune cell cancer therapy
ZA202309516B (en) Anti-ccr8 antibodies
PH12021551241A1 (en) Expansion of natural killer cells and ilc3 cells with novel aromatic compounds
PH12022553144A1 (en) Immune cells with enhanced function
EP4588484A3 (en) Methods of treating multiple myeloma
MX2024013608A (es) Particula viral con moleculas estimuladoras de superficie
WO2021168119A3 (en) Methods and compositions for identifying and treating subjects at risk of poor cancer survival
MX2021009626A (es) Metodos y composiciones para el tratamiento de gastritis de celulas cebadas, esofagitis de celulas cebadas, enteritis de celulas cebadas, duodenitis de celulas cebadas y/o gastroenteritis de celulas cebadas.
WO2022082014A3 (en) Skin targeted immunotolerance
WO2021081457A3 (en) Methods and agents for enhancing t cell therapies
WO2022272292A3 (en) Engineered cells for therapy
ZA202305072B (en) Cd1a antibodies and uses thereof
MX2021008834A (es) Metodos de tratamiento del cancer de mama con tucatinib.
WO2020036646A3 (en) Cancer neoantigens and their utilities in cancer vaccines and tcr-based cancer immunotherapy
WO2024006292A3 (en) Methods of treating cancer
WO2021041716A3 (en) Therapeutic editing to treat cardiomyopathy
MX2022013622A (es) Partículas con carga negativa para el tratamiento contra síndrome de tormenta de citocinas (css) y síndrome de insuficiencia respiratoria aguda (ards).
AU2020363707A8 (en) In vitro methods and compositions for enhancing the activation of dendritic cells and t cells, and for inducing a th-1 immune response